Navigation Links
Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
Date:11/21/2007

SEATTLE, Nov. 21 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that Dr. Peter Thompson, president, chief executive officer and chairman of Trubion, is scheduled to present a corporate update at the upcoming Lazard Capital Markets Healthcare Investor Conference to be held at The New York Palace Hotel. Dr. Thompson is scheduled to present Nov. 27, 2007, at 2:30 p.m. Interested parties may access the live audio webcast of the presentation by visiting the Wall Street Webcasting link at http://www.wsw.com/webcast/lz4/trbn.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP(TM) custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information, visit

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... ERT (Nasdaq: ERES ), a leading provider of ... biopharmaceutical, medical device, and related industries, announced today that it ... Thursday, October 29, 2009 after the market closes. After the ... PM EDT that day. , For the conference call, ...
... A faster tool for cell programming and a new ... grand prizes of the 2009 Collegiate Inventors Competition, a program ... Abbott Fund, the non-profit foundation of the global health care ... (USPTO). Harris Wang, who invented a new way of ...
... 21 BioWa, Inc. (BioWa) and NKT Therapeutics, ... into an agreement which provides NKTT with access ... development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. ... research, develop, manufacture and commercialize antibodies targeting natural ...
Cached Biology Technology:ERT to Announce 2009 Third Quarter Results on October 29, 2009 2Winners Announced in 2009 Collegiate Inventors Competition(R) 2Winners Announced in 2009 Collegiate Inventors Competition(R) 3Winners Announced in 2009 Collegiate Inventors Competition(R) 4Winners Announced in 2009 Collegiate Inventors Competition(R) 5Winners Announced in 2009 Collegiate Inventors Competition(R) 6Winners Announced in 2009 Collegiate Inventors Competition(R) 7BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 2BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 3
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
(Date:4/17/2014)... many serious conditions such as heart disease, epilepsy and ... therapies. Unfortunately, there is still much scientists do not ... and unexpected insight into the structure of sodium channels ... - which are responsible for ,fine-tuning, the activity of ... recent edition of the Journal of Biological Chemistry ...
(Date:4/17/2014)... Ind. -- Indiana University researchers have detected new early-warning ... diabetes. This discovery could have far-reaching implications for the ... care of over 25 million Americans. , "We had ... retinas at such early stages," said Ann Elsner, professor ... and lead author of the study. "We set out ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Structure of sodium channels different than previously believed 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... a commercially viable method for mass producing effective vaccines ... the months required for traditional egg-based vaccines. They report ... , The next flu pandemic could happen any time," ... (PSC) and a researcher on the study. "The ...
... click as Cornell University researchers have fabricated a set ... receptors on cell membranes and trigger larger-scale responses within ... an allergic response. , How cell membranes control cellular ... However, nanotechnology now gives researchers new tools to understand ...
... Not all biological weapons are created equal. They are ... agents being the scariest: They are easy to spread, ... pubic health system. One of these worrisome organisms is ... media attention. But work in Vince Fischetti's laboratory at ...
Cached Biology News:New influenza vaccine takes weeks to mass produce 2'Nano-keys' bind cell receptors and trigger allergic reactions 2'Nano-keys' bind cell receptors and trigger allergic reactions 3Newly discovered protein kills anthrax bacteria by exploding their cell walls 2
... Avian Myeloblastosis Virus Reverse Transcriptase (AMV RT) ... DNA, RNA or RNA:DNA hybrids (1). It ... efficient than RNA primers) as well as ... intrinsic RNase H activity. Both nonionic detergents ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... is a preparation of deoxyribonuclease I ... to produce 3-hydroxyl oligonucleotides. This preparation ... where maintaining the integrity of RNA ... for use with the Core Footprinting ...
... Liquid. In 100 mM KCl, 20 ... 20% glycerol, pH 7.9. AVOID FREEZE/THAW CYCLES. Human ... protein of 765 amino acids encoded by a ... positive and negative supercoiled DNAs without the requirement ...
Biology Products: